In vitro activity of tigecycline against 313 Gram-positive and Gram-negative clinical isolates
AbstractObjectives. In this study the in vitro activity of tigecycline, member of a new class of antimicrobial agents, the glycylcyclines, was evaluated against clinical isolates collected in Italy. Study Design. A total of 313 clinical pathogens were collected and identified in our Institution during 2007-2008. Minimum inhibitory concentrations (MICs) of the antimicrobial agents were determined by the CLSI (2007) recommended broth microdilution method. Results. Globally 205 Gram-negative and 108 Gram-positive pathogens were evaluated.Tigecycline demonstrated excellent inhibitory activity against Acinetobacter spp., H. influenzae, E. coli, Enterococcus spp., S. aureus, S. agalactiae and S. pneumoniae with MIC90 ≤1mg/l. Conclusion. Tigecycline exhibited potent in vitro antibacterial activity (comparable to or greater than most commonly employed antimicrobials) against both Gram-positive and negative clinical pathogens.These data suggest that tigecycline, with an expanded broad-spectrum antimicrobial activity, may be an effective empiric therapeutic option for the treatment of serious infections caused by clinically relevant pathogens.
- Abstract views: 1170
- PDF: 610
Copyright (c) 2010 Elisabetta Maioli, Erika Coppo, Ramona Barbieri, Elisabetta Canepa, Laura Gualco, Carla Pruzzo, Eugenio A. Debbia, Anna Marchese
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.